Company Overview
Venus Concept Inc. operates as a medical technology company focused on the development, commercialization, and delivery of minimally invasive and non-invasive medical aesthetic and hair restoration technologies alongside related services in both the United States and international markets. The company functions within the Healthcare sector, specifically targeting the Medical Devices industry, where it aims to provide specialized solutions for aesthetic and restorative procedures. Venus Concept Inc. maintains a market capitalization of $626,524, generates annual revenue of $58.88M, and employs a workforce of 292 individuals. These financial figures indicate that the company operates on a relatively small scale within the broader healthcare landscape, positioning it as a micro-cap entity with modest revenue generation compared to larger established medical device peers. The low market capitalization combined with the specific focus on niche aesthetic technologies suggests the company is in an early-stage or niche-focused growth phase rather than a mature, diversified industrial operation.
Financial Health
The company reported revenue of $58.88M over the trailing twelve months, yet this generated a net income of $-54,614,000, revealing a significant disparity between top-line sales and bottom-line profitability. This substantial gap between revenue and net income indicates a highly aggressive cost structure where operating expenses significantly outweigh gross profits, resulting in a net loss that is more than double the revenue figure. EBITDA stands at $-30,890,000, which further highlights the intense cash burn occurring before non-cash adjustments like depreciation and amortization. Free cash flow is negative at $-12,040,125, indicating that the company is consuming cash reserves rather than generating liquidity, which limits its financial flexibility and ability to fund operations without external capital. Despite the losses, the company maintains a gross margin of 64.4%, suggesting that the core product portfolio retains value well against the cost of goods sold before overheads are applied. However, the operating margin is a negative 68.9% and the profit margin is a severe -92.8%, indicating that high fixed costs or selling, general, and administrative expenses are eroding profitability to a critical extent. In terms of balance sheet leverage, the company holds $4.31M in cash against $32.67M in debt, resulting in a debt-to-equity ratio of 1042.31, which signifies a highly leveraged position where liabilities exceed equity tenfold. The current ratio stands at 0.91, indicating that current assets are insufficient to cover current liabilities without relying on external financing or asset sales. Return on Equity is -794.5% and Return on Assets is -32.4%, metrics that reveal management is currently unable to generate positive returns on the capital invested by shareholders or utilized in assets.
Valuation Assessment
The company presents a trailing P/E ratio of N/A due to negative earnings, while the forward P/E is listed as -0.15, implying that the market expects earnings to remain negative or that valuation is being driven by non-earnings multiples. The price-to-book ratio is 0.23, indicating that the stock trades at a significant discount to its book value, which often suggests market skepticism regarding the quality of assets or the ability to monetize them at full value. The price-to-sales ratio is 0.01, and the EV/EBITDA is -0.95, suggesting that traditional valuation multiples are either negative or not applicable, reflecting the high risk profile associated with the company's financial structure. Regarding price action, the 52-week high is $14.50 and the 52-week low is $0.26, meaning the stock has experienced extreme volatility and currently trades well below its recent peak, potentially reflecting a correction from a previous speculative surge. The beta value is 0.06, which indicates that the stock price exhibits negligible volatility relative to the broader market, moving independently of general market trends with very low sensitivity to macroeconomic fluctuations.
Growth & Income
Revenue growth year-over-year is -8.2%, while earnings growth is N/A due to the company's ongoing losses, implying that the business is currently contracting rather than expanding its top line. The absence of earnings growth combined with negative revenue growth suggests that the company is struggling to maintain market share or grow its customer base in a competitive medical device environment. As the company does not pay dividends, the dividend yield is N/A and the payout ratio is 0.0%, indicating that the company retains all available cash to fund operations or reduce debt rather than distributing income to shareholders. Consequently, the overall growth and income profile is characterized by negative revenue momentum, a complete lack of dividend income, and a reliance on external capital markets to sustain operations while attempting to reverse the downward trend in sales.